Keywords: celltech, anti-tnf, phase, study, completed, cdp571, recombinant

CELLTECH'S ANTI-TNF: PHASE I STUDY

Article | 10 May 1993

Print This

Celltech has completed a Phase I study of CDP571, a recombinant humanized antibody which blocks the action of tumor necrosis ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in